Denali Therapeutics Inc. — fact timeline

Denali Therapeutics Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-06-03 meeting.

“Advisory Vote to Approve Executive Compensation The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.”

Denali Therapeutics Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-03 meeting.

“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting:”

Denali Therapeutics Inc. shareholders approved Election of three Class III directors at the 2026-06-03 meeting.

“Election of three Class III directors to hold office until the 2029 annual meeting of stockholders. Each of the following nominees was elected to serve as a Class III director, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”

Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.

“On May 7, 2026, Denali Therapeutics Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2026.”

Denali Therapeutics Inc. terminated Collaboration Agreement with Takeda Pharmaceutical Company Limited (effective 2018-01-03).

“On April 3, 2026, Denali Therapeutics Inc. (“Denali”) received written notice from Takeda Pharmaceutical Company Limited (“Takeda”) of its decision to terminate the Collaboration Agreement (the “Agreement”), dated January 3, 2018, between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN).”

Denali Therapeutics Inc. reported the first quarter ended March 31, 2024 results: revenue There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended, net income Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter.

“Net loss was $101.8 million for the quarter ended March 31, 2024, compared to net loss of $109.8 million for the quarter ended March 31, 2023. There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended March 31, 2023.”

Denali Therapeutics Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

“Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights.”

Denali Therapeutics Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $500 million (effective 2024-02-27).

“On February 27, 2024, Denali Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 3,244,689 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at $17.07 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 26,046,065 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $17.06 per Pre-Funded Warrant.”